Theratope cancer vaccine data

BIOMF presented Phase II data indicating that patients with metastatic cancer who develop strong antibody responses to Theratope have a statistically significant survival advantage over those patients who don't develop an immune response.

As presented at the International Congress on Anti-Cancer Treatment in Paris, 26 evaluable patients with metastatic ovarian cancer were treated with 100 µg of Theratope after platinum-based chemotherapy. ...